Valneva SE (VALN)
NASDAQ: VALN · IEX Real-Time Price · USD
7.25
0.00 (-0.07%)
At close: Jul 26, 2024, 3:59 PM
7.28
+0.03 (0.41%)
After-hours: Jul 26, 2024, 4:00 PM EDT
Valneva SE Revenue
Valneva SE had revenue of 32.75M EUR in the quarter ending March 31, 2024, a decrease of -2.25%. This brings the company's revenue in the last twelve months to 152.96M, down -58.99% year-over-year. In the year 2023, Valneva SE had annual revenue of 153.71M, down -57.46%.
Revenue (ttm)
152.96M EUR
Revenue Growth
-58.99%
P/S Ratio
3.03
Revenue / Employee
226,268 EUR
Employees
676
Market Cap
504.43M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Enhabit | 1.04B |
Sharecare | 419.82M |
Pacific Biosciences of California | 200.43M |
Treace Medical Concepts | 196.03M |
Voyager Therapeutics | 119.04M |
Theravance Biopharma | 61.51M |
Jin Medical International | 19.82M |
Absci | 5.35M |
VALN News
- 4 days ago - CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World's First Chikungunya Vaccine - GlobeNewsWire
- 8 days ago - Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026 - Benzinga
- 9 days ago - Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion - GlobeNewsWire
- 25 days ago - Valneva Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, IXCHIQ® - GlobeNewsWire
- 4 weeks ago - Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board - GlobeNewsWire
- 4 weeks ago - Valneva Announces Health Canada Approval of the World's First Chikungunya Vaccine, IXCHIQ® - GlobeNewsWire
- 7 weeks ago - Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June - GlobeNewsWire